| Followers | 236 |
| Posts | 10817 |
| Boards Moderated | 0 |
| Alias Born | 07/17/2006 |
Thursday, May 14, 2020 10:21:21 AM
CaptBeer...
While I read and agree with most of your post. I think you and most of the board are missing the main point....
The trial is not about obviousness...The trial is about Property..If you read all my posts you will agree that no one on this board is any more convinced there was no obviousness about the unexpected benefits of using pure EPA in adequate doses..
But that is just a side issue...The real issue is Amarin did all the heavy lifting, spent all the money, endured the roadblocks that FDA put up at every cross road and that is why Amarin should be considered the Property owner of the EPA franchise with all rights as guaranteed by Hatch-Waxman and should be protected by the law..and not be subject to a Kangaroo Court orchestrated by a judge who for whatever reason is neither impartial or even honest and is obviously determined to give Amarin's property to the generics who have done nothing to deserve the drug rights except go to court and convince some crooked judge they own the property rights..
I have not seen one post that suggests the generics have spent one dollar to research this drug and its indication to get FDA approval in the USA.
If this is the way the law works in this country then woe to us all..Obviousness my foot...The only thing that was really obvious was the R-I trial far exceeded the expectations of virtually all cardiologists and that was a fact regardless of what Mori or Kura said or didn't say..
I gather from our learned lawyers on the board that the AC decision breaks down into a crap shoot depending on the ideology of the particular judges we draw..Jesus..is it really come to that..Is there no one in the law that believes in right and wrong..My only daughter is a lawyer..
I know in medicine..therapeutics is not regulated by political beliefs or ideologies..Ignorance is still the biggest factor..
":>) JL
While I read and agree with most of your post. I think you and most of the board are missing the main point....
The trial is not about obviousness...The trial is about Property..If you read all my posts you will agree that no one on this board is any more convinced there was no obviousness about the unexpected benefits of using pure EPA in adequate doses..
But that is just a side issue...The real issue is Amarin did all the heavy lifting, spent all the money, endured the roadblocks that FDA put up at every cross road and that is why Amarin should be considered the Property owner of the EPA franchise with all rights as guaranteed by Hatch-Waxman and should be protected by the law..and not be subject to a Kangaroo Court orchestrated by a judge who for whatever reason is neither impartial or even honest and is obviously determined to give Amarin's property to the generics who have done nothing to deserve the drug rights except go to court and convince some crooked judge they own the property rights..
I have not seen one post that suggests the generics have spent one dollar to research this drug and its indication to get FDA approval in the USA.
If this is the way the law works in this country then woe to us all..Obviousness my foot...The only thing that was really obvious was the R-I trial far exceeded the expectations of virtually all cardiologists and that was a fact regardless of what Mori or Kura said or didn't say..
I gather from our learned lawyers on the board that the AC decision breaks down into a crap shoot depending on the ideology of the particular judges we draw..Jesus..is it really come to that..Is there no one in the law that believes in right and wrong..My only daughter is a lawyer..
I know in medicine..therapeutics is not regulated by political beliefs or ideologies..Ignorance is still the biggest factor..
":>) JL
Recent AMRN News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/22/2026 09:00:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:02 PM
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 25, 2026 • GlobeNewswire Inc. • 02/11/2026 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:06 AM
